C hronic hepatitis C virus (HCV) infection is 1 of the leading causes of liver-related morbidity and mortality in the United States and many other countries. 1, 2 While the exact prevalence in most cases of chronic HCV infection in the United States is unknown, estimates from the 2003-2010 National Health and Nutrition Examination Survey (NHANES)-a sample of the civilian noninstitutionalized population of the United States-indicate that at least w1% have chronic HCV infection. 3 Nonetheless, the burden of HCV infection is much higher in some subgroups of the population, with estimates ranging from 6% to 35% in male Veterans 4 and from 10% to 46% among incarcerated individuals.
Updated national data are needed for public health planning, especially in the context of the major recent therapeutic advances for the treatment of HCV infection that have substantially improved prognosis. 6 Of particular interest is documenting the full burden and implications of comorbid conditions such as obesity, diabetes, and kidney disease among individuals with HCV. According to current clinical guidelines, chronic hepatitis C patients with comorbidities such as human immunodeficiency virus or advanced fibrosis have the highest urgency for treatment as their risk for progression is very high. 7, 8 A number of studies suggest comorbidities such as obesity and diabetes are also associated with increased risk for progression. [9] [10] [11] However, to our knowledge, the current the burden of common comorbidities among individuals with chronic hepatitis C in the U.S. population is unknown, and their prognostic significance remains unproven. Such data are critical given new screening and treatment guidelines that recommend universal screening among baby-boomers and, from a public health perspective, the need to prioritize patients for treatment in the setting of the high costs and limited resources.
We analyzed the most recent national data from the 1999-2012 NHANES to provide estimates of the prevalence of chronic hepatitis C and the burden of comorbid conditions in individuals infected with chronic hepatitis C in the general U.S. population. We also pooled data from NHANES III (1988 III ( -1994 with the continuous NHANES (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) surveys to comprehensively examine the risk of all-cause and cause-specific death (cardiovascular or cancer) among individuals with chronic hepatitis C alone or in combination with other comorbidities.
Methods
The plan and operation of NHANES can be found in elsewhere. 12, 13 Briefly, the NHANES are cross-sectional, multistage, stratified, clustered probability samples of the U.S. civilian noninstitutionalized population conducted by the National Center for Health Statistics, a branch of the Centers for Disease Control and Prevention. Individuals participated in an interview conducted at home and also in an extensive physical examination performed at a Mobile Examination Center, which included blood collection.
For the current analyses, we limited our study population to NHANES 1999-2012 participants aged 20 years or older who provided a blood sample and were not missing antibodies to HCV (anti-HCV) and HCV RNA (viral load) test results. We further excluded individuals with missing data on important covariates, for a total analytical sample of n¼23,691. To enhance our sample size for mortality analyses, we also included 13,726 NHANES III (1988-1994) participants aged 20 years or older who were not missing anti-HCV and HCV RNA test results or other important covariates.
The NHANES protocol was reviewed and approved by the Institutional Review Board of the Centers for Disease Control and Prevention and all participants provided written informed consent.
In the NHANES 1999-2012, serum samples were analyzed for anti-HCV using Ortho HCV enzyme-linked immunosorbent assay (ELISA), version 3.0 (OrthoClinical Diagnostics). Specimens that tested positive were then tested using a confirmatory recombinant immunoblot assay (RIBA HCV 3.0 Strip Immunoblot Assay, Chiron). Samples with positive results on both tests are classified as confirmed positive for anti-HCV. Samples that were anti-HCV positive or indeterminate were further tested for HCV RNA using a nucleic acid amplification test for the quantitation of HCV RNA (COBAS AMPLICOR HCV Test [survey years , and COBAS AmpliPrep/TaqMan HCV Test, version 2 [years 1999-2004] ). Individuals were considered anti-HCV negative if they either had a negative ELISA or had a positive ELISA not confirmed by RIBA. Individuals were considered chronically infected if they had detectable HCV RNA.
In NHANES III, serum samples were tested for anti-HCV using a second-generation ELISA test (EIA 2.0) and a confirmatory test (HCV MATRIX, Abbott Laboratories). Samples with positive results on the HCV MATRIX were considered positive for anti-hepatitis C. Samples that were anti-HCV positive were further tested for HCV RNA using reverse transcriptase polymerase chain reaction methods.
Additional details regarding methods are described in the Supplement.
Statistical Analyses
We accounted for the complex NHANES sampling design in all analyses and incorporated sampling weights to generate nationally representative estimates. We used the Taylor series (linearization) method to calculate the standard errors.
To estimate the number of persons with chronic hepatitis C or who were anti-HCV positive, we applied our prevalence estimates to the 2010 U.S. Census Population. We used logistic models, adjusting for age, sex, and race or ethnicity, and used predictive margins to estimate the adjusted prevalence of selected comorbidities by chronic hepatitis C or anti-HCV status.
For the mortality analyses, we pooled data from NHANES 1999-2010 and NHANES III and used Poisson regression models with adjustment for age, age squared, sex, and race or ethnicity to estimate the adjusted mortality rates and 95% confidence intervals (CIs) by chronic hepatitis C status with or without selected comorbidities. Hazard ratios (HRs) and 95% CIs of allcause, cardiovascular, and cancer mortality according to chronic hepatitis C status, with or without other comorbidity, were estimated using Cox proportional hazards regression, with age as the timescale. We used 3 models: Model 1 included sex, race or ethnicity, and education; Model 2 further adjusted for smoking and alcohol consumption; and Model 3 further adjusted for diabetes, hypertension, albuminuria, and body mass index.
Kaplan-Meier survival curves were used to compare the mortality by key subgroups defined by the following comorbidities: chronic hepatitis C, diabetes, obesity, and any chronic kidney disease. We excluded participants with events or lost to follow up before 45 years of age. All analyses were conducted using Stata/SE version 13 (StataCorp, College Station, TX).
Results
During 1999-2012, in the U.S. general, noninstitutionalized, adult population, the overall prevalence of anti-HCV positivity was 1.8% (95% CI, 1.6%-2.0%), representing approximately 4 million (95% CI, 3.5-4.4) adults aged 20 years or older in 2010. The overall prevalence of chronic hepatitis C was 1.2% (95% CI, 1.0%-1.4%), or 2.6 million (95% CI, 2.30-3.03) adults. As shown in Figure 1 , there are marked differences in the prevalence of chronic hepatitis C (and anti-HCV positivity) by age and birth cohort, and over time there has been a shift in the distribution from younger to older age, consistent with the aging of the "baby boomer" population (ie, those persons who were born in the years . Across survey periods, there was not a significant trend in the prevalence of chronic hepatitis C (Supplementary Figure 1) .
There was a higher prevalence of chronic hepatitis C among non-Hispanic blacks, men, persons at or below poverty threshold, and persons with less than high school of education (Supplementary Table 1 ). Individuals with chronic hepatitis C were significantly more likely to report a history of injection drug use (52.4% vs 2.2%; P < .001) or a history of blood transfusion (24.5% vs 11.2%; P < .001), as compared with their counterparts without chronic hepatitis C. Additionally, individuals with chronic hepatitis C were more likely to be anti-HBc positive (34.3% vs 4.8%; P < .001) or human immunodeficiency virus positive (1.2% vs 0.4%; P ¼ .02); however, there was not a statistically significant difference in the prevalence of hepatitis B surface antigen positivity by HCV status (0.7% vs 0.3%; P ¼ .19). Persons with chronic hepatitis C were substantially more likely to report current smoking (62.0% vs 22.2%; P < .001), high current alcohol consumption (61.5% vs 40.7%) or being a former drinker (16.4% vs 9.2%; P < .001) (Supplementary Table 2 ).
Even after accounting for demographic differences, persons with chronic hepatitis C were disproportionally affected by major metabolic, cardiovascular, and renal comorbidities (Table 1) . Indeed, despite a lower prevalence of obesity (21.7% vs 33.3%; P < .001) persons with chronic hepatitis C had a higher prevalence of diabetes (16.1% vs 9.1%; P ¼ .02) as compared with persons without chronic hepatitis C. Based on these data, it can be estimated that in 2010, approximately 418,000 U.S. adults (95% CI, 200,000-700,000) had both chronic hepatitis C and diabetes, a similar number of individuals had chronic hepatitis C and albuminuria, and approximately 600,000 (95% CI, 300,000-800,000) had both chronic hepatitis C and obesity. Hypertension, prevalent cardiovascular disease, and albuminuria were all significantly more common in persons with chronic hepatitis C (Table 1) . Overall, 69.6% (95% CI, 62.1%-76.2%) of persons with chronic hepatitis C had at least 1 of the following cardiometabolic and renal comorbidities: diabetes, obesity, hypertension, hypercholesterolemia, reduced kidney function, or macroalbuminuria.
There were substantial disparities in measures of healthcare access and utilization related to chronic hepatitis C status, with 20.9% of persons with hepatitis C reporting no routine place for health care and 36% reporting no health insurance. Further, individuals with chronic hepatitis C were significantly more likely to have had 1 or more hospitalizations in the past 12 months and more days with poor physical and mental health compared with those without chronic hepatitis C (Supplementary Table 3 ).
Only 38% of those with chronic hepatitis C reported physician diagnosis of any liver disease, yet persons with chronic hepatitis C had significantly higher prevalence of liver-related laboratory abnormalities: more than twothirds of those with chronic hepatitis C had elevated liver enzymes and 14% had elevated aspartate aminotransferase to platelet ratio index (!1.5), suggesting the presence of significant liver fibrosis (Table 2) .
There were few individuals who were anti-HCV positive and HCV RNA negative (n¼123), compared with these individuals, those with chronic hepatitis C were older; more likely to be male, non-Hispanic Black, at or below poverty threshold; had less than high school of education; were more likely to be current smokers; and were more likely to report high current alcohol consumption. Furthermore, individuals with chronic hepatitis C had higher prevalence of hypertension and liver-related abnormalities, but were less likely to have obesity compared with those with anti-HCV positive and HCV RNA negative results (Supplementary Table 4) .
During a median follow up of 8.7 years (range, 1-23 years), there were 5988 deaths (including 1800 from cardiovascular causes, and 1367 from cancer) among 36,198 persons with mortality follow up. The incidence rates of death in persons with chronic hepatitis C vs those without were: 16.1 vs 10.7 per 1000 person-years (P < .01).
Chronic hepatitis C was associated with a significantly increased risk of all-cause mortality (HR, 3.47; 95% CI, 2.56-4.70) ( Table 3 ). This association was somewhat attenuated but remained elevated after adjustment for sociodemographic characteristics, alcohol consumption, and smoking (HR, 2.45; 95% CI, 1.81-3.31). Further adjustment for comorbidities did not appreciably alter these results. Individuals with chronic hepatitis C were at significantly increased risk of cardiovascular mortality (HR, 2.55; 95% CI, 1.38-4.71). This association remained elevated even after further adjustment for sociodemographic characteristics, alcohol, and smoking and comorbidities (HR, 1.86; 95% CI, 1.04-3.35). Only among those fasting and in the morning exam. b Lowest sex-specific quartile of each lipid parameter: total cholesterol <177 mg/dL for men and <180 mg/dL for women; LDL cholesterol: <100 mg/dL for men and <96 for women; HDL cholesterol: <38 mg/dL for men and <46 mg/dL for women; triglycerides: <90 mg/dL for men and <79 mg/dL for women.
In the analyses examining the mortality across key subgroups defined by the presence of comorbidities, the absolute risk of death in persons with chronic hepatitis C was substantially higher among those with diabetes compared with those without diabetes (adjusted mortality rate per 1000 person-years, 247.8 vs 139.8).
Among chronic hepatitis C patients with and without chronic kidney disease, the adjusted mortality rates were 210.0 vs 131.5 per 1000 person-years, respectively. In the setting of chronic hepatitis C, both diabetes and chronic kidney disease were associated with substantially reduced survival: median survival was 9 years lower in persons with diabetes and 8.5 years lower in persons with chronic kidney disease (Figure 2 and Supplementary Table 5) .
Discussion
This study provides rigorous quantification of the comorbid status of HCV-infected patients in the general U.S. noninstitutionalized population. Overall, 70% of persons with chronic hepatitis C had at least 1 of the following cardiometabolic and renal comorbidities: diabetes, obesity, hypertension, hypercholesterolemia, reduced kidney function, or macroalbuminuria. The high prevalence of obesity and diabetes in persons with chronic hepatitis C is noteworthy and worrisome given the association of diabetes and obesity, with faster progression of liver disease to fibrosis and cirrhosis. 10, 11, [14] [15] [16] We documented an increased risk of not only total mortality but also cardiovascular mortality among individuals with hepatitis C infection (HR, 2.55). This association was attenuated but remained significant (HR, 1.85) after adjusting for traditional cardiovascular risk factors. To our knowledge, this is a novel finding and further studies are needed to examine the mechanisms and explore specific cardiovascular disease subtypes that may be driving the observed association. Our study demonstrated a substantially increased risk of death among persons with both chronic hepatitis C and diabetes or chronic kidney disease in the general population. These results are important given that both chronic kidney disease and diabetes have reached epidemic proportions in the general U.S population and also among those with hepatitis C, particularly in older adults. Recent randomized clinical trials of direct-acting antivirals have demonstrated that more than 90% patients can achieve sustained virological response; however, the vast majority of clinical trials testing the effects of treatments in chronic hepatitis C have included relatively homogeneous populations and have tended to show universal benefit. Indeed, few trials have included substantial numbers of overweight or obese persons or many persons with diabetes. Further, patients with low kidney function have generally been excluded from recent trials. [17] [18] [19] [20] Most of the recent trials have focused on subgroups defined by genotype of the hepatitis C virus, liver fibrosis stage, or parameters of severity of the infection (eg, viral load); more effort is needed to assess the effectiveness of treatment in patients with common comorbid conditions.
The association between hepatitis C and diabetes and chronic kidney disease has been reported previously, including prior studies using NHANES data. [21] [22] [23] [24] [25] [26] [27] [28] Previous NHANES studies have also provided valuable information on the overall hepatitis C prevalence (up until 2010) 3, 29, 30 and key risk factors. 3, [29] [30] [31] Our study expands on prior work in NHANES on the epidemiology of hepatitis C in the general U.S. population and extend these findings in 2 major ways: our study provides the most recent national estimates of the overall burden of chronic hepatitis C and of common comorbid conditions (obesity, diabetes, chronic kidney disease) in the setting of hepatitis C in U.S. adults. We also provide estimates of the risk of total and cause-specific mortality associated with HCV in the presence and absence of these important and common comorbid conditions, in the general U.S. population, a previous study had reported an increased risk of all-cause mortality but did not include data regarding cardiovascular mortality. 32 Our study has certain limitations that should be considered in the interpretation of these results. With the exception of the mortality analyses, our study was cross-sectional and therefore we cannot establish the temporality of the observed associations. In addition, for some conditions, we relied on self-reported data, which is likely to be highly specific for most medial conditions but likely resulted in some degree of under ascertainment. NHANES does not include incarcerated individuals, persons in nursing homes, hospitals, or those who are homeless, all populations who are disproportionally affected by HCV infection. 5, 33 Thus, our prevalence estimates are likely to be underestimates of the true burden of chronic hepatitis C in the United States. Combining estimates from noninstitutionalized, institutionalized samples and other sources (eg, Indian reservations), Edlin et al 34 estimated that at least 3.5 millions U.S. adults are currently infected with HCV. There were only a very small number of individuals who were anti-HCV positive and HCV RNA negative, preventing us from rigorously examining this subgroup. For individuals with chronic hepatitis C we did not have information on treatment. Last, we were neither able to examine associations with causes of death other than cancer or cardiovascular disease nor able to examine specific cardiovascular mortality subtypes.
Strengths of our study include the large and nationally representative sample of civilian noninstitutionalized U.S. adults in NHANES. We were able to examine a comprehensive number of demographic, socioeconomic, health-care related variables and objectively and rigorously measured health conditions. All measurements were obtained by trained personnel using standardized data collection procedures and protocols.
In conclusion, our results highlight the significant burden of comorbid conditions in patients with chronic hepatitis C and the substantial excess risk of mortality in persons with chronic hepatitis C who also have diabetes and chronic kidney disease, 2 highly prevalent conditions in the United States. These findings have important implications for clinical practice and public health planning and should help to inform current controversies regarding prioritization of treatment and public health planning efforts.
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Methods
Other Measures and Study Definitions
National Health and Nutrition Examination Survey (NHANES) participants answered standard questionnaires to obtain data on: sex, age, race or ethnicity (categorized as recommended by the Centers for Disease Control and Prevention/National Center for Health Statistics as non-Hispanic white, non-Hispanic black, Mexican-American, or other (including multiracial or other Hispanic), education, income, smoking, alcohol consumption, past blood transfusion, hospital utilization in the last 12 months, health insurance, access to care, and medical history. Health-related quality of life (HRQOL) and disability were assessed using the CDC's Core HRQOL Module. 1 Information about sexual behavior and injection drug use was collected only in participants aged 20-59 years per NHANES protocol.
Standardized measurements of height, weight, waist circumference, and systolic and diastolic blood pressure were measured at the Mobile Examination Center. Body mass index was calculated dividing weight in kilograms by height in meters squared.
Standard laboratory methods were used for the following serum biochemistries: albumin, bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase, total cholesterol, high-density lipoprotein cholesterol, creatinine, and fasting triglycerides. Fasting low-density lipoprotein cholesterol was calculated using the Friedewald equation. Other laboratory tests included fasting plasma glucose, complete blood count, and urinary albumin and creatinine from a random spot urine sample.
Serum specimens were tested for hepatitis B surface antigen (AUSZYME, Abbot Laboratories) and antibody to hepatitis B core antigen (ORTHO hepatitis B core enzyme-linked immunosorbent assay). Positive hepatitis B surface antigens were repeat tested in duplicate. Specimens positive in either of the repeat tests were considered positive.
HIV-1/HIV-2 antibody status was assessed using the synthetic peptide enzyme immunoassay (Genetic Systems HIV-1/HIV-2 Peptide EIA). Reactive specimens were retested in duplicate. Positive tests were then tested using the Cambridge Biotech HIV-1 Western Blot Kit (Calypte Biomedical Corporation, Rockville, MD).
We defined diabetes as a self-reported physician diagnosis or fasting plasma glucose !126 mg/dL. Hypertension was defined as a self-reported physician diagnosis or mean blood pressure !140/90 mm Hg. History of cardiovascular disease was defined as history of physician diagnosis of coronary heart disease, heart attack, or stroke. History of cancer was defined as history of physician diagnosis of cancer.
Estimated glomerular filtration rate (eGFR) was estimated using the Chronic Kidney DiseaseEpidemiology Collaboration 2009 equation based on age, sex, race, and serum creatinine. 2 Albuminuria was defined as !30 mg/g. Reduced kidney function was defined as eGFR <60 mL/min/1.73 m 2 . Any chronic kidney disease was defined as eGFR <90 mL/min/ 1.73 m 2 or albuminuria !30 mg/g, representing chronic kidney disease stage 1 or greater based on a modified chronic kidney disease classification established by the National Kidney Foundation Disease Outcomes Quality Initiative. 3 Hypolipidemia traits were defined as the lowest sexspecific quartile of each lipid parameter 4 : total cholesterol <177 mg/dL for men and <180 mg/dL for women; fasting low-density lipoprotein cholesterol <100 mg/dL for men and <96 for women; high-density lipoprotein cholesterol <38 mg/dL for men and <46 mg/dL for women; and fasting triglycerides <90 mg/dL for men and <79 mg/dL for women. Anemia was defined as hemoglobin <12 g/dL among women and <13.5 g/dL among men.
We examined the following liver related measures: awareness of liver disease (yes/no) was based on the answer to the following question: "Has a doctor or other health professional ever told you that you had any kind of liver condition? And categorized as yes or no. Elevated liver enzymes were defined by the upper limit of normal of the NHANES laboratory values (ALT >41 U/L among men and >31 U/L among women; AST >37 U/L among men and >31 U/L among women; gamma-glutamyl transferase: >49 U/L among men and >32 U/L among women). We used the following noninvasive indices of liver fibrosis: aspartate aminotransferase-to-platelet ratio index and Fibrosis-4 (FIB-4). We calculated aminotransferase-to-platelet ratio index as ([AST/upper limit of normal] / platelet count [109/L]) Â 100, and categorized as elevated using 2 previously described cutoffs for fibrosis (0.5 and 1.5).
5 FIB-4 was calculated as
Elevated FIB-4 was defined as FIB-4 >1.30.
6 Low albumin was defined as albumin <3.5 mg/dL. Low platelet count was defined as platelets <100,000 Â 10 3 cells/mL.
Linked Mortality
To determine the vital status and cause of death, the National Center for Health Statistics linked NHANES participants aged 20 years and older who participated in the NHANES III and in NHANES 1999-2010 surveys to the National Death Index. Presently, follow-up extends from the date of the NHANES examination through the date of death or December 31, 2011. Cause of death was determined from the underlying cause of death listed on the death certificate and coded according to the International Classification of Disease-Tenth Revision. NOTE. Values are % or mean AE SD. APRI, aminotransferase-to-platelet ratio index; eGFR, estimated glomerular filtration rate; FIB-4, Fibrosis 4; HCV, hepatitis C virus; PIR, poverty income ratio.
